日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

通过 IN-DEPTH 进行同一张载玻片空间多组学整合,揭示了肿瘤病毒相关的肿瘤微环境空间重组。

Yiu Stephanie Pei Tung, Chang Yuzhou, Yeo Yao Yu, Qiu Huaying, Wu Wenrui, Michel Hendrik A, Jin Xiaojie, Huang Rongting, Kure Shoko, Parmelee Lindsay, Luo Shuli, Cramer Precious, Lee Jia Le, Wang Yang, Zhao Zhangxin, Yeung Jason, El Ahmar Nourhan, Simsek Berkay, Mohanna Razan, Van Orden McKayla, Lu Wesley S, Livak Kenneth J, Li Shuqiang, Gao Ce, Burgess Melinda, Keane Colm, Shahryari Jahanbanoo, Kingsley Leandra G, Al-Humadi Reem N, Nasr Sahar, Nkosi Dingani, Sadigh Sam, Rock Philip, Frauenfeld Leonie, Kaufmann Louisa, Zhu Bokai, Basak Ankit, Dhanikonda Nagendra, Chan Chi Ngai, Krull Jordan, Cho Ye Won, Chen Chia-Yu, Brown Jonathan, Wang Hongbo, Zhao Bo, Lee Jia-Ying Joey, Loo Lit-Hsin, Kim David M, Boussiotis Vassiliki A, Zhang Baochun, Wei Kevin, Shalek Alex K, Howitt Brooke E, Signoretti Sabina, Schürch Christian M, Hodi F Stephen, Burack W Richard, Rodig Scott J, Ma Qin, Jiang Sizun

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

晚期黑色素瘤患者接受纳武利尤单抗联合伊匹木单抗治疗的最终10年疗效

Wolchok, Jedd D; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Cowey, C Lance; Schadendorf, Dirk; Wagstaff, John; Queirolo, Paola; Dummer, Reinhard; Butler, Marcus O; Hill, Andrew G; Postow, Michael A; Gaudy-Marqueste, Caroline; Medina, Theresa; Lao, Christopher D; Walker, John; Márquez-Rodas, Iván; Haanen, John B A G; Guidoboni, Massimo; Maio, Michele; Schöffski, Patrick; Carlino, Matteo S; Sandhu, Shahneen; Lebbé, Céleste; Ascierto, Paolo A; Long, Georgina V; Ritchings, Corey; Nassar, Ayman; Askelson, Margarita; Benito, Melanie Pe; Wang, Wenjia; Hodi, F Stephen; Larkin, James

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

遗传性线粒体基因作为黑色素瘤免疫检查点抑制剂疗效的预测因子

Monson, Kelsey R; Ferguson, Robert; Handzlik, Joanna E; Morales, Leah; Xiong, Jiahan; Chat, Vylyny; Dagayev, Sasha; Khodadadi-Jamayran, Alireza; Simpson, Danny; Kazlow, Esther; Bunis, Anabelle; Sreenivasaiah, Chaitra; Ibrahim, Milad; Voloshyna, Iryna; Ouwerkerk, Wouter; Luiten, Rosalie M; Capone, Mariaelena; Madonna, Gabriele; Lu, Yuting; Shao, Yongzhao; Pavlick, Anna; Krogsgaard, Michelle; Mehnert, Janice; Tang, Hao; Dolfi, Sonia; Tenney, Daniel; Haanen, John B A G; Gajewski, Thomas F; Hodi, F Stephen; Flaherty, Keith T; Couts, Kasey; Robinson, William; Puzanov, Igor; Ernstoff, Marc S; Rahma, Osama; Postow, Michael; Sullivan, Ryan J; Luke, Jason J; Ascierto, Paolo A; Osman, Iman; Kirchhoff, Tomas

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204

CheckMate 204 研究中接受纳武利尤单抗联合伊匹木单抗治疗的黑色素瘤脑转移患者的颅内反应评估标准比较分析

Huang, Raymond Y; Youssef, Gilbert; Nelson, Thomas; Wen, Patrick Y; Forsyth, Peter; Hodi, F Stephen; Margolin, Kim; Algazi, Alain P; Hamid, Omid; Lao, Christopher D; Ernstoff, Marc S; Moschos, Stergios J; Atkins, Michael B; Postow, Michael A; Reardon, David A; Grootendorst, Diederik J; Leung, David; Askelson, Margarita; Ritchings, Corey; Tawbi, Hussein A

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047

RELATIVITY-047 研究显示,在晚期黑色素瘤患者中,使用纳武利尤单抗联合瑞拉利单抗治疗的三年总生存期为 3 年。

Tawbi, Hussein A; Hodi, F Stephen; Lipson, Evan J; Schadendorf, Dirk; Ascierto, Paolo A; Matamala, Luis; Castillo Gutiérrez, Erika; Rutkowski, Piotr; Gogas, Helen; Lao, Christopher D; Janoski De Menezes, Juliana; Dalle, Stéphane; Arance, Ana Maria; Grob, Jean-Jacques; Ratto, Barbara; Rodriguez, Saima; Mazzei, Antonella; Dolfi, Sonia; Long, Georgina V

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

更正:一线治疗晚期黑色素瘤:纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗联合伊匹木单抗:基于 RELATIVITY-047 和 CheckMate 067 试验数据的间接治疗比较

Long, Georgina V; Lipson, Evan J; Hodi, F Stephen; Ascierto, Paolo A; Larkin, James; Lao, Christopher; Grob, Jean-Jacques; Ejzykowicz, Flavia; Moshyk, Andriy; Garcia-Horton, Viviana; Zhou, Zheng-Yi; Xin, Yiqiao; Palaia, Jennell; McDonald, Laura; Keidel, Sarah; Salvatore, Anthony; Patel, Divya; Sakkal, Leon A; Tawbi, Hussein; Schadendorf, Dirk

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

纳武利尤单抗联合伊匹木单抗或单用纳武利尤单抗治疗晚期黑色素瘤患者的长期汇总结果

Long, Georgina V; Larkin, James; Schadendorf, Dirk; Grob, Jean-Jacques; Lao, Christopher D; Márquez-Rodas, Iván; Wagstaff, John; Lebbé, Céleste; Pigozzo, Jacopo; Robert, Caroline; Ascierto, Paolo A; Atkinson, Victoria; Postow, Michael A; Atkins, Michael B; Sznol, Mario; Callahan, Margaret K; Topalian, Suzanne L; Sosman, Jeffrey A; Kotapati, Srividya; Thakkar, Pratik K; Ritchings, Corey; Pe Benito, Melanie; Re, Sandra; Soleymani, Samira; Hodi, F Stephen

MON-282 Referral Patterns and Perceptions of Interventional Radiologists in Adrenal Vein Sampling (AVS): A Survey of the American Association of Endocrine Surgeons

MON-282 肾上腺静脉取样(AVS)中介入放射科医生的转诊模式和认知:美国内分泌外科医师协会的一项调查

Chang, Lee-Shing; Barroso-Sousa, Romualdo; Tolaney, Sara M; Hodi, F Stephen; Kaiser, Ursula B; Min, Le; Neff, Marisela; Kozlowski, Konrad; Lin, Jack; Issa, Chloe; Patel, Anmol; Clode, Hannah; Pennix, Thomas; Vaghaiwalla, Tanaz; Lew, John I; Miller, Zoe

Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis

免疫检查点抑制剂相关静脉血栓栓塞风险:一项综合分析

Sussman, Tamara A; Giobbie-Hurder, Anita; Dryg, Ian D; Manos, Michael; Weirather, Jason L; LeBoeuf, Nicole R; Hodi, F Stephen; Connors, Jean M

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial

快速整合生物标志物项目为免疫肿瘤学临床试验提供信息:ADVISE试验的理论依据和可行性

Luke, Jason J; Bever, Katherine; Hodi, F Stephen; Taube, Janis; Massey, Ashish; Yao, David; Neely, Jaclyn; Tam, Rachel; Lee, George; Gupta, Akshita; Dutta, Santanu; Szabo, Peter; Bao, Riyue; Reilly, Tim